Immunotherapy in the First-Line Treatment of NSCLC: Current Status and Future Directions in China
Lung cancer causes significant morbidity and mortality in China and worldwide. In China, lung cancer accounts for nearly one-fourth of all cancer deaths. Non-small cell lung cancer (NSCLC) is the predominant type of lung cancer, accounting for approximately 80%–85% of all lung cancer cases. Immunoth...
Enregistré dans:
Auteurs principaux: | Anwen Xiong, Jiali Wang, Caicun Zhou |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Frontiers Media S.A.
2021
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/85401136b19c4d6bb7c8f3bf245ae86f |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Progress in the Application of Immune Checkpoint Inhibitor-Based Immunotherapy for Targeting Different Types of Colorectal Cancer
par: Rui He, et autres
Publié: (2021) -
Immune Checkpoint Inhibitors With or Without Bone-Targeted Therapy in NSCLC Patients With Bone Metastases and Prognostic Significance of Neutrophil-to-Lymphocyte Ratio
par: Alberto Bongiovanni, et autres
Publié: (2021) -
New PD-L1 inhibitors in non-small cell lung cancer – impact of atezolizumab
par: Seetharamu N, et autres
Publié: (2017) -
Role of Immune Checkpoint Inhibitor Therapy in Advanced EGFR-Mutant Non-Small Cell Lung Cancer
par: Nathaniel Wiest, et autres
Publié: (2021) -
MET Amplification and Efficacy of Nivolumab in Patients With NSCLC
par: Katsuhiro Yoshimura, MD, PhD, et autres
Publié: (2021)